9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report

Termination Date

12/31/2013

11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

12. Lobbying

13. Organizations

INCOME relating to lobbying activities
for this reporting period was:

EXPENSE relating to lobbying activities
for this reporting period were:

Less than $5,000

Less than $5,000

$5,000 or more

$

45,000.00

$5,000 or more

$

Provide a good faith estimate, rounded to the nearest
$10,000,
of all lobbying related income from the client (including all
payments to the registrant by any other entity for lobbying
activities on behalf of the client).

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

15. General issue area code BUD

16. Specific lobbying issues

S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs

17. House(s) of Congress and Federal agencies
Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Sharon

Cohen

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​​Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, laws or regulation, commercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

15. General issue area code HCR

16. Specific lobbying issues

Implementation of the new health care reform law - PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage, the essential benefit pkg., and other matters.

17. House(s) of Congress and Federal agencies
Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Sharon

Cohen

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​​Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, laws or regulation, commercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

15. General issue area code MMM

16. Specific lobbying issues

S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 -- Continuing Appropriations Resolution, 2014 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs

17. House(s) of Congress and Federal agencies
Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Sharon

Cohen

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​​Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, laws or regulation, commercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Sharon

Cohen

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​​Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, laws or regulation, commercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.